Search results
Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls
Zacks via Yahoo Finance· 3 months agoBiogen BIIB reported fourth-quarter 2023 adjusted earnings per share (EPS) of $2.95, which missed...
New Alzheimer's drug from Biogen, Eisai gets government approval, but faces long road ahead
Yahoo Finance· 11 months agoA new Alzheimer's drug from Eisai and Biogen (BIIB) is now fully approved by the FDA, opening the...
Biogen Skids Despite Beat-And-Raise Quarter As Pressure Builds In Alzheimer's Market
Investor's Business Daily· 2 years agoBiogen stock toppled within a profit-taking zone Tuesday despite a beat-and-raise earnings report...
Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's
Zacks via Yahoo Finance· 1 year agoFDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental...
Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump
Investor's Business Daily· 12 months agoBiogen stock jumped into a buy zone Thursday after Medicare officials said they would reimburse...
Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement
Zacks via Yahoo Finance· 11 months agoAn FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's...
Biogen Stock Surges After Two Notable Products Walloped Sales Expectations
Investor's Business Daily· 1 month agoTwo of Biogen's newest drugs, Leqembi and Skyclarys, walloped first-quarter sales expectations on...
Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?
Motley Fool· 11 months agoBiogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies. Biogen turned...
Is Biogen a Smart Biotech Stock to Buy Right Now?
Motley Fool· 2 years agoTens of millions of Alzheimer's disease patients were given a rare dose of good news recently when Biogen (NASDAQ: BIIB) released some encouraging...
Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment
Zacks via Yahoo Finance· 10 months agoIt was a busy week for the biotech sector, with many important regulatory and pipeline updates....